| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.04 |
| mRNA | STF-62247 | GDSC1000 | pan-cancer | AAC | -0.066 | 0.04 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | -0.075 | 0.04 |
| mRNA | MLN4924 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.04 |
| mRNA | WZ3105 | GDSC1000 | pan-cancer | AAC | 0.059 | 0.05 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.077 | 0.05 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.05 |
| mRNA | FK866 | CTRPv2 | pan-cancer | AAC | -0.08 | 0.05 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.08 | 0.05 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.076 | 0.05 |